NCT06907056View on ClinicalTrials.gov

Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Versus Darunavir/Cobicistat Plus Tenofovir/Emtricitabine in Virologically Suppressed HIV-1-positive Individuals in Mexico

PHASE4RecruitingINTERVENTIONAL

Enrollment

138

Participants

Timeline

Start Date

November 9, 2023

Primary Completion Date

February 28, 2026

Study Completion Date

November 30, 2026

Conditions

HIV Infection

Interventions

DRUG

dual therapy

Intervention arm will be dual therapy oh DRV/C 800/150 mg + 3TC 300 mg, this will be compared to standar therapy of 3 drugs with: DRV/c 800/150 mg + TDF/FTC 300/200 mg

DRUG

Standard Medical Therapy

DRV/c+TDF/FTC

Trial Locations (1)

02990

RECRUITING

Hospital de Infectología, Centro Médico Nacional La Raza, Mexico City

All Listed Sponsors

lead

José Antonio Mata Marín

OTHER_GOV

NCT06907056 - Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Versus Darunavir/Cobicistat Plus Tenofovir/Emtricitabine in Virologically Suppressed HIV-1-positive Individuals in Mexico | Biotech Hunter | Biotech Hunter